The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the…
NEW YORK CITY, NY / ACCESS Newswire / September 26, 2025 / African Heads of State and Government convened global…
FORT LAUDERDALE, Fla., Sept. 26, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII),…
HYDERABAD, India, Sept. 26, 2025 /PRNewswire/ -- According to a recent report by Mordor Intelligence, the medical drones market size…
FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support…
MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway…
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made…
BCRF responds to scientific community's urgent need to sustain research NEW YORK, Sept. 24, 2025 /PRNewswire/ -- At a time…
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every…
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell…